CSPC Pharmaceutical has seized the chance of entry into the third national centralized procurement and expects stable sales for the generic drug Celecoxib.
Image credit: EqualOcean
CSPC Pharma’s Celecoxib is the generic COX-2 form of Celebrex, used to treat pain and inflammation in osteoarthritis, acute pain in rheumatoid arthritis, ankylosing spondylitis, painful menstruation and other related syndromes.
As released officially today, CSPC’s Celecoxib was approved by the National Medical Products Administration, which is seen as an approval of the consistency evaluation for generic drugs. The medicine has been listed in the third national centralized procurement and selected for the third national centralized procurement.
CSPC Pharmaceutical, together with two brands (Hengrui Medicine and Zhengda Qingjiang Pharmacy) of the generic drugs of Celecoxib, will compete against the original developer Pfizer in procurement supplies.
The First Move of the U.S. Postal Service on Cross-Border E-commerce After Trump
Feb 21, 2025 08:19 PM
Shanghai and Shenzhen: The Dual-City Landscape and Corporate Power
Jan 09, 2025 03:35 PM